Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

CRISPR Therapeutics Reports Results From Phase 1 CARBON Trial Of CTX110 In Relapsed, Refractory CD19+ B-Cell Malignancies: ‘58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose’

-58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis- -Durable responses in

CRSP

Read More

Cathie Wood’s ARK Invest Posts Fund Purchases For Thursday, Aug. 19, 2021: PLTR, ZY, SURF, SRNG, SMFR, RPTX, DYNS, QSI, MASS, VCYT, TSP, SGFY, NTLA, EDIT, CRSP, BEAM, SPFR, MKFG, KMTUY, AVAV, GENI, KVSB, LPSN

Palantir Technologies (PLTR) - 368,311 Shares Zymergen (ZY) - 109,777 Surface Oncology (SURF) - 86,170 Soaring Eagle Acquistion (SRNG) - 435,860 Sema4 (SMFR) - 176,046 Repare Therapeutics (RPTX) - 18,596 Dynamics

AVAV

Read More

Cathie Wood’s ARK Invest Posts Fund Purchases For Wednesday, Aug. 18, 2021: PATH, PLTR, Z, RPTX, SURF, QSI, VCYT, PFE, NVTA, ZY, MASS, EXAS, DYNS, CRSP, SMFR, TSP, SRNG, SGFY, NTLA, BEAM, FATE, EDIT, AVAV, BLDE, KMTUY, MKFG, CND, GENI, KVSB, LPSN

UiPath (PATH) - 80,400 Shares Palantir Technologies (PLTR) - 93,189 Zillow Group (Z) - 21,507 Repare Therapeutics (RPTX) - 3,791 Surface Oncology (SURF) - 41,741 Quantum-Si (QSI) - 130,116 Veracyte (VCYT) -

AVAV

Read More

Cathie Wood’s ARK Invest Posts Fund Purchases For Tuesday, Aug. 17, 2021: PLTR, Z, RPTX, VCYT, QSI, ZY, NTLA, MASS, EDIT, DYNS, CRSP, BLI, SMFR, FATE, EXAS, SGFY, BEAM, NVTA, AVAV, MKFG, BLDE, KMTUY, RBLX, LPSN, KVSB, CND

Palantir Technologies (PLTR) - 476,114 Shares Zillow Group (Z) - 2,800 Repare Therapeutics (RPTX) - 8,967 Veracyte (VCYT) - 40,152 Quantum-Si (QSI) - 163,972 Zymergen (ZY) - 136,853 Intellia Therapeutics (NTLA) -

AVAV